Compare American Well Corp (AMWL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Moderna, Inc. — how do they compare? American Well Corp trades at $12.5 (market cap $220.94M), while Moderna, Inc. trades at $64.06 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 109.4× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| AMWL | MRNA | |
|---|---|---|
Market Cap | $220.94M | $24.18B |
Sector | Health | Health |
52-Week High | $13.58 | $81.80 |
52-Week Low | $3.78 | $22.36 |
Enterprise Value | $27.98M | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $12.93, down 4.79% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q2 2026 revenue of $52 million, beating estimates, and continues to narrow losses, targeting cash-flow breakeven by Q4 2026. Recent news includes a key executive joining Amazon's healthcare unit, highlighting strategic relevance.
Outlook hinges on achieving profitability targets amid declining revenues. Opportunities include operational efficiency gains and high-profile partnerships, but risks persist from sustained net losses and competitive pressures. Analyst consensus is cautious with 67% hold ratings.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
